Deborah Neesham
Overview
Explore the profile of Deborah Neesham including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
356
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McBain R, Kashyap A, Bishop M, Vicario E, Volchek M, Naaman Y, et al.
Aust N Z J Obstet Gynaecol
. 2024 Oct;
PMID: 39428825
Introduction: Borderline ovarian tumours (BOT) are a common epithelial ovarian tumours. Typically diagnosed at an early stage with a good prognosis, many BOT are treated conservatively. Recurrence is common. This...
2.
Preston M, McBain R, Rajadevan N, Jones A, Neesham D, McNally O
Aust N Z J Obstet Gynaecol
. 2024 May;
64(6):573-579.
PMID: 38715341
Background: Sentinel lymph node (SLN) dissection has been established as standard of care in many tumours. Its use in early cervical cancer is an area of increasing interest and some...
3.
Tan J, Neesham D, Szabo R, Khomko N, Yap D, Wrede C
Aust N Z J Obstet Gynaecol
. 2024 Mar;
64(4):375-382.
PMID: 38425311
Aims: To assess colposcopic performance and determine indicators for competency within the new Australian primary human papillomavirus (HPV) cervical screening program. Materials And Methods: A retrospective observational study of 4542...
4.
McInerney C, McNally O, Cade T, Jones A, Neesham D, Naaman Y
Aust N Z J Obstet Gynaecol
. 2023 Nov;
64(3):223-229.
PMID: 37964485
Background: Gestational trophoblastic disease (GTD) is an uncommon but highly treatable condition. There is limited local evidence to guide therapy. Aims: To report the experience of a statewide registry in...
5.
Kondrashova O, Ho G, Au-Yeung G, Leas L, Boughtwood T, Alsop K, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-18.
PMID: 35100705
Purpose: The ALLOCATE study was designed as a pilot to demonstrate the feasibility and clinical utility of real-time targeted molecular profiling of patients with recurrent or advanced ovarian cancer for...
6.
Rajadevan N, McNally O, Neesham D, Richards A, Naaman Y
Aust N Z J Obstet Gynaecol
. 2021 Feb;
61(2):284-289.
PMID: 33528032
Background: Human epididymis protein 4 (HE4) has shown promising utility as a prognostic biomarker in endometrial cancer. Increased serum HE4 levels may be associated with deeper myometrial invasion, extrauterine disease...
7.
Neesham D, Richards A, McGauran M
Aust J Gen Pract
. 2020 Oct;
49(10):665-669.
PMID: 33015682
Background: Most epithelial ovarian cancer occurs in older women, with a mean age at diagnosis of 62 years and an overall five‑year survival rate in Australia of 43%. Most women...
8.
Playdon M, Nagle C, Ibiebele T, Ferrucci L, Protani M, Carter J, et al.
Br J Cancer
. 2017 May;
116(12):1627-1637.
PMID: 28463959
Background: The relationship between diet and survival after ovarian cancer diagnosis is unclear as a result of a limited number of studies and inconsistent findings. Methods: We examined the association...
9.
Janda M, Gebski V, Davies L, Forder P, Brand A, Hogg R, et al.
JAMA
. 2017 Mar;
317(12):1224-1233.
PMID: 28350928
Importance: Standard treatment for endometrial cancer involves removal of the uterus, tubes, ovaries, and lymph nodes. Few randomized trials have compared disease-free survival outcomes for surgical approaches. Objective: To investigate...
10.
Black C, Feng A, Bittinger S, Quinn M, Neesham D, McNally O
Int J Gynecol Cancer
. 2015 Nov;
26(1):133-40.
PMID: 26588230
Objective: Uterine papillary serous carcinoma (UPSC) is a rare variant of endometrial carcinoma responsible for up to 40% of endometrial cancer deaths. Controversy remains regarding optimal adjuvant therapy for UPSC,...